Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With $5B under management, a diversified fund and over 190 exits to date, Canaan has invested in some of the world's leading technology and healthcare companies over the past 30 years. Canaan’s focus areas include fintech, enterprise/cloud, marketplaces, frontier tech, biopharma, digital health, and medtech.

Canaan Partners

[Connecticut Innovations](http://www.ctinnovations.com) provides strategic capital and operational insight to to companies in high-tech industries such as energy, biotechnology, information technology, and photonics. Their mission is to be the leading source of financing and ongoing support for Connecticut’s innovative, growing companies. By offering flexible financing, strategic guidance and introductions to valuable partners, Connecticut innovations enable promising businesses to thrive.

Connecticut Innovations

5AM Ventures is a venture capital firm that offers seed- and early-stage investments to its clients. The company’s client portfolio consists of firms in the biopharmaceutical, life sciences, medical technology, and research instrument industries. 5AM Ventures was founded in 2002 by John Diekman and Andrew Schwab and is based in California.

5AM Ventures

ESVC principal strategy is to create and initially operate life sciences companies founded on intellectual property developed at Yale University and other research institutions in the region (from New York City through Southern New England).  With experienced management and access to local, professionally managed venture capital, Elm Street Ventures can help scientists build significant technology companies from the seed and early stage. Our partners include successful serial entrepreneurs and experienced corporate managers, who may serve as the interim CEOs or operating chairmen of a number of the companies we form.  While they expect to be co-founders of companies in some circumstances, ESVC are also interested in hearing from entrepreneurs, scientists, and engineers who have already formed or plan to form new ventures in the life sciences.  Attractive markets, solid patent protection and freedom to operate, defensible market position, and a world class management team are elements ultimately critical for success.

Elm Street Ventures

New Leaf Venture Partners is a venture capital firm that invests primarily in healthcare technology. The company typically focuses on later stage biopharmaceutical products, early stage medical devices, and laboratory infrastructure technologies.  The New Leaf Ventures (NLV) team has been built over a decade, originating within Sprout Group, the venture capital affiliate of Credit Suisse First Boston. Sprout Group was formed in 1969 and has historically been one of the leading venture capital firms in the country. The team started to invest in healthcare technology in 1993 and since then, has become a leading venture investor in that sector. In 2005, the entire healthcare technology team of Sprout spun out into NLV.

New Leaf Venture Partners

OrbiMed is a healthcare-dedicated investment firm, with approximately $5 billion in assets under management. OrbiMed's investment advisory business was founded in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies. OrbiMed manages the Caduceus Private Investments series of venture capital funds and a family of public equity investment funds.

OrbiMed

RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and board levels. The company invests in companies with promising technologies and products.

RA Capital Management

Founded in 2005, Hillhouse is a leading global investment management firm, active across public equity, private equity, real estate and private credit. The firm invests over a long-term horizon and partners with exceptional entrepreneurs to deliver sustainable value creation for quality companies. Hillhouse is a full life-cycle private equity firm, investing for the long term across opportunities in the healthcare, business services, consumer, and industrials sectors. The firm manages capital on behalf of global institutions such as non-profit foundations, endowments, and pensions.

Hillhouse Investment

Nextech Invest is a venture capital and private equity firm specializing in early, mid-stage, late-stage, and emerging growth investments. The firm also invests in incorporation, spin-outs, reverse-take-over, and PIPE transactions. It only considers investments where evidence in preclinical animal models that a drug is efficacious is available or a device prototype fulfills the requirements. The firm seeks to invest in the field of information technology, biotechnology, and healthcare with a focus on oncology companies developing cancer drugs and diagnostics. It prefers to invest in life science and enabling technologies with a focus on interdisciplinary technical and scientific projects, therapies, diagnostics, medical technologies, and services. The firm seeks to invest in companies based in Africa, the Middle East, Asia, North America, and Europe including Switzerland, Germany, and neighboring regions. It also considers co-investments in the rest of Europe. The firm seeks to invest between CHF 1 million ($0.93 million) and CHF 5 million ($4.7 million) per financing round. It seeks a Board position in the portfolio companies. The firm seeks to exit its investments within three years via trade sale.

Nextech Invest

Deerfield is an investment management firm. They provide a healthcare ecosystem through information and investment. They also provide private and public investments across the life science, medical device, diagnostic, digital health, and health service industries.

Deerfield

Sirona Capital is a real estate firm that focusses on property investment, development, and urban renewal.

Sirona Capital

Arvinas

Oerth Bio is a developer of targeted protein degraders for agricultural applications. The company leverages Arvinas' novel PROTAC protein degrader technology to develop new human therapeutics for patients with cardiovascular, oncological, and gynecological diseases.

Arvinas is a pharmaceutical company that focuses on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Its proprietary approach is the targeting of disease-causing proteins for degradation thus eliminating them from the body.

<div>
  <p>
    Arvinas is a clinical stage biopharmaceutical company that focuses on treatments and therapies for cancers and diseases that are challenging to treat. The company has developed PROTAC protein degraders, which use the natural protein disposal system present in the body to eliminate disease-causing proteins. This is used to treat prostate and breast cancers. Arvinas is also developing PROTAC protein degraders for central nervous system targets, which has the potential to treat neurodegenerative diseases among other therapeutic areas. Its pipeline largely consists of oncology treating therapies and neuroscience programs. The company is publicly held.&nbsp;
  </p>
  <p>
  </p>
</div>


Arvinas

Company Brief

Funding

Investors

Portfolio

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless